Leukemia Cells Current Events | Page 25

Leukemia Cells Current Events, Leukemia Cells News Articles.
Sort By: Most Viewed | Most Recent
Page 25 of 25 | 1000 Results
Revolutionary Bone Marrow Transplantation Procedure Inaugurated At Yale Cancer Center
A new form of bone marrow and stem cell transplantation between partially-mismatched, related donors, Haplotype MisMatch Transplants -- will soon be available at the Yale Cancer Center. The technique allows transplants between parents, siblings or children. (1997-12-05)

Small gene changes in some leukemia patients may explain varying responses to chemotherapy
A new study in the May 5 issue of the Journal of the National Cancer Institute provides evidence that may explain why some patients with chronic lymphocytic leukemia (CLL) are resistant to chemotherapy and have a shorter survival time and may identify a potential new target for treating the disease. (2004-05-04)

Ottawa researchers find Achilles' heel of a severe form of childhood leukemia
Researchers at The Ottawa Hospital and the University of Ottawa have found the Achilles' heel of one of the most aggressive forms of leukemia that affects both children and adults. They have also identified a possible new treatment that exploits this fatal weakness. (2016-03-02)

Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
Retroviruses have potential for gene therapy only if they do not activate endogenous genes. Of three tested retroviral vectors, ASLV showed no preference for integration into human transcription start regions. (2004-08-16)

Two genetic mutations discovered in subset of acute myeloid leukemia
Two genetic mutations known to play a role in many solid cancers might also help explain why a subset of acute myeloid leukemia (AML) patients develop the disease. (2016-12-07)

Sylvester presents latest cancer research at ASH Annual Meeting
Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will present a selection of the latest advances in hematology research at this year's American Society of Hematology Annual Meeting, Dec. 5-8, at the Orange County Convention Center in Orlando, Fla. (2015-12-02)

Champlin earns Transplant Society's Lifetime Achievement Award
The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21. (2011-02-21)

Why chemotherapy fails
Tracing the lineage tree of recurring leukemia cells provides evidence for slowly dividing cancer stem cells that resist chemotherapy as the source of the recurrence. (2012-05-29)

Patrick Stiff, M.D., awarded Loyola's Stritch Medal
Patrick J. Stiff, M.D., a world renowned cancer physician, researcher and teacher, has received the Stritch Medal, the highest honor given by Loyola University Chicago Stritch School of Medicine. (2016-11-28)

Benzene responsible for high percentage of leukemia deaths induced by smoking
Benzene, a potent chemical found in cigarette smoke and automobile emissions, appears responsible for between 8 percent and 48 percent of all smoking-induced leukemia deaths, a new University of North Carolina at Chapel Hill study indicates. The chemical also causes between 12 percent and 58 percent of smoking-related deaths from acute myeloid leukemia. (2000-05-03)

Drug target identified for common childhood blood cancer
In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified a possible new drug target for treating the disease. (2014-07-31)

Clinical study shows biological and clinical activity in relapsed leukemia patients
Promising interim results from ongoing Phase 2 Chronic Lymphocytic Leukemia clinical trial indicate that single-agent GCS-100 induces apoptosis (programmed cell death) in patients' CLL cells, reduces leukocyte count in some patients and is generally well-tolerated. GCS-100 targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The compound has potential to be a low toxic alternative to current treatments, for use as single agent or in combination therapy. (2008-06-04)

DNA methylation pattern in leukemia only appears to be cancer-typical
The pattern of epigenetic labels in the DNA of cancer cells differs from that of healthy cells. This has been considered a characteristic of cancer. Scientists from the German Cancer Research Center have now discovered in blood cancer that the labeling pattern of the cancer cells more likely reflects the maturation stage of cancer precursor cells at the moment of carcinogenesis, rather than representing a cancer-typical variation. (2016-01-18)

Cure Rate Soars For Some AML Patients Receiving High-Dose Drug
When the drug cytarabine is given at levels substantially higher than the standard dose, it can cure nearly five times as many patients who have a certain type of acute myeloid leukemia (AML), compared to the standard dose of the drug, according to new research. (1998-10-29)

Early infusion of donor T cells prevents graft versus host disease in blood cancer patients
A study published today in Blood, the Journal of the American Society of Hematology, highlights updated results for a potential new strategy for preventing graft-versus-host disease and promoting the patient's immune system recovery after hematopoietic stem cell transplantation. (2011-02-03)

St. Jude leukemia therapy overcomes differences in treatment outcome between black, white children
Investigators at St. Jude Children's Research Hospital have found that black children are equally likely as white children to benefit from improved treatment for acute lymphoblastic leukemia (ALL), if given equal access to the most advanced therapies. (2003-10-14)

Sinai team builds first model acute myeloid leukemia progression using CRISPR
A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February. (2021-02-10)

New lab test could identify imatinib resistance
Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia. (2010-07-29)

UCLA scientists prove endothelial cells give rise to blood stem cells
Stem cell researchers at UCLA have proven definitively that blood stem cells are made during mid-gestational embryonic development by endothelial cells, the cells that line the inside of blood vessels. (2008-12-03)

UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
A new study by UC Davis researchers provides evidence that methods using human bone marrow-derived stem cells to deliver gene therapy to cure diseases of the blood, bone marrow and certain types of cancer do not cause the development of tumors or leukemia. (2008-05-06)

Elsevier launches new open access journal: 'Leukemia Research Reports'
Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open access, online journal, Leukemia Research Reports. (2012-11-22)

The bone marrow is the source of mature liver cells
In a finding that opens a new avenue to treating liver disease and blood clotting disorders, researchers have found that the bone marrow is the source of cells that are responsible for the liver's famous ability to regenerate itself. (2000-06-25)

Life-Saving Discrepancy: Study Shows Effectiveness Of Mismatched Bone Marrow Transplants
A method for performing mismatched bone marrow treatments in leukemia patients developed by Weizmann scientist Prof. Yair Reisner and Prof. Massimo Martelli of Perugia University now shows with statistics success rates equal to those transplants performed with perfectly matched transplants. (1998-10-22)

Mouse model highlights histone methylation as distinguishing feature for leukemia subtypes
Research using a new mouse model has led to the identification of a potential therapeutic target for a type of leukemia commonly associated with an unfavorable prognosis. The study, published by Cell Press in the November issue of the journal Cancer Cell, also validates examination of histone modification as a strategy for distinguishing cancer subtypes. (2008-11-03)

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease. A new study bolsters the evidence that this approach is safe for most patients under careful clinical oversight. (2020-06-04)

Novel compound turns off mutant cancer gene in animals with leukemia
A compound discovered and developed by a team of Georgetown Lombardi Comprehensive Cancer Center researchers that halts cancer in animals with Ewing sarcoma and prostate cancer appears to work against some forms of leukemia, too. That finding and the team's latest work was published in Oncotarget. (2015-10-09)

CT scans may increase the risk of brain cancer
A new study in the Journal of the National Cancer Institute suggests that CT scans, commonly used in medical imaging, may increase the risk of brain tumors. (2018-07-18)

Potential targeted therapy found for newly identified leukemia subtype with poor outcome
St. Jude Children's Research Hospital-led study expands understanding of the genetic basis of acute lymphoblastic leukemia subtypes and identifies possible targeted therapy for some patients at risk for a poor outcome. (2016-11-08)

TSRI scientists discover mechanism that turns mutant cells into aggressive cancers
Scientists at The Scripps Research Institute have caught a cancer-causing mutation in the act. A new study shows how a gene mutation found in several human cancers, including leukemia, gliomas and melanoma, promotes the growth of aggressive tumors. (2016-05-26)

Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse?
'Recent studies suggest that epigenetic modifications may contribute to the development of cancer progenitor cells that can induce drug resistance and the relapse of different types of cancer,' said Sibaji Sarkar, Ph.D., instructor of medicine at BUSM. Adult drug resistant cancer cells may contribute to this problem, and the authors discuss these and other cancer drug resistance mechanisms in their recent publication in the September issue of the journal Cancers. (2014-09-16)

UCSB researchers discover the processes leading to acute myeloid leukemia
Researchers at UC Santa Barbara have discovered a molecular pathway that may explain how a particularly deadly form of cancer develops. The discovery may lead to new cancer therapies that reprogram cells instead of killing them. The findings are published in a recent paper in the Journal of Biological Chemistry. (2012-01-30)

CRI scientists discover vitamin C regulates stem cell function, curbs leukemia development
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern has found that stem cells take up unusually high levels of vitamin C, which then regulates their function and suppresses the development of leukemia. (2017-08-21)

Leukemia patients who switched kinase inhibitors had favorable outcomes
Chronic lymphocytic leukemia patients who stopped taking the kinase inhibitors, ibrutinib or idelalisib, had mostly favorable outcomes when they switched to the alternate therapy. (2015-12-07)

Van Andel Institute researchers find gene that could lead to new therapies for bone marrow disease
Van Andel Research Institute researchers are one step closer to finding new ways to treat myelodysplastic syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia. Researchers found that the gene RhoB is important to the disease's progression and could prove to be a therapeutic target for late-stage MDS. (2009-09-28)

Research leads to new treatment recommendations for a high-risk pediatric leukemia
International researchers led by St. Jude Children's Research Hospital have identified genetic alterations that can be used to guide treatment of pediatric acute megakaryoblastic leukemia, which has a dismal prognosis. (2017-01-23)

New tipifarnib (R115777) data in AML presented at American Society of Hematology Annual Meeting
Data on tipifarnib (R115777), a compound under investigation by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. for the treatment of elderly patients with newly diagnosed poor-risk acute myeloid leukemia (AML), were presented at the 46th annual meeting of the American Society of Hematology (ASH). (2004-12-06)

Leukemic cells find safe haven in bone marrow
The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to investigators at St. Jude Children's Research Hospital. (2007-03-22)

Identified a key protein in the generation of B lymphocytes
Researchers of the Cellular Differentiation Group of IDIBELL have identified a transcriptional repressor, the histone deacetylase HDAC7, involved in the generation and the identity of B lymphocytes, the cells responsible to create antibodies in our immune system. (2016-10-17)

African-Americans and women are less likely to undergo bone marrow transplantation
African-Americans and women are less likely than Caucasians and men to undergo bone marrow transplantation to treat cancers of the blood. That is the conclusion of a new analysis published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The study's results indicate that additional research is needed to determine why disparities exist in access to bone marrow transplantation and also that the medical community should work to eliminate these inequities. (2010-05-24)

Engineers model mutations causing drug resistance
Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and 'second generation' approaches are needed. Now, a team of Penn State engineers may have a way to predict which mutations will occur in people, creating an easier path to create effective pharmaceuticals. (2020-03-24)

Page 25 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.